Compositions and methods for inhibiting arginase activity
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
1. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the cancer is selected from acute myeloid leukemia (AML), bladder cancer, breast cancer, colorectal cancer, chronic myelogenous leukemia (CML), esophageal cancer, gastric cancer, lung cancer, melanoma, mesothelioma, non-small cell lung carcinoma (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, bile duct cancer, multiple myeloma, adrenocortical carcinoma, head and neck cancer, and endometrial cancer.
3. The method of claim 1 comprising conjointly administering one or more additional chemotherapeutic agents.
4. The method of claim 3 , wherein the one or more additional chemotherapeutic agents includes aminoglutethimide, amsacrine, anastrozole, asparaginase, AZD5363, Bacillus CalmetteGurin vaccine (bcg), bicalutamide, bleomycin, bortezomib, buserelin, busulfan, campothecin, capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, chloroquine, cisplatin, cladribine, clodronate, cobimetinib, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin, dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide, levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, metformin, methotrexate, miltefosine, mitomycin, mitotane, mitoxantrone, MK-2206, nilutamide, nocodazole, octreotide, olaparib, oxaliplatin, paclitaxel, pamidronate, pazopanib, pentostatin, perifosine, plicamycin, pomalidomide, porfimer, procarbazine, raltitrexed, rituximab, rucaparib, selumetinib, sorafenib, streptozocin, sunitinib, suramin, talazoparib, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide, thioguanine, thiotepa, titanocene dichloride, topotecan, trametinib, trastuzumab, tretinoin, veliparib, vinblastine, vincristine, vindesine, or vinorelbine.
5. The method of claim 3 , wherein the one or more additional chemotherapeutic agents includes abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab, atezolizumab, avelumab, blinatumomab, BMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab, indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, MED14736, MPDL3280A, nivolumab, ocaratuzumab, ofatumumab, olatatumab, pembrolizumab, pidilizumab, rituximab, ticilimumab, samalizumab, or tremelimumab.
6. The method of claim 3 , wherein the one or more additional chemotherapeutic agents includes abagovomab, adecatumumab, afutuzumab, anatumomab mafenatox, apolizumab, blinatumomab, catumaxomab, durvalumab, epratuzumab, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab, nivolumab, ocaratuzumab, olatatumab, pembrolizumab, pidilizumab, ticilimumab, samalizumab, or tremelimumab.
7. The method of claim 6 , wherein the one or more additional chemotherapeutic agents includes ipilimumab, nivolumab, pembrolizumab, or pidilizumab.
8. The method of claim 1 , wherein the method further comprises administering one or more non-chemical methods of cancer treatment selected from, such as radiation therapy, surgery, thermoablation, focused ultrasound therapy, cryotherapy, or a combination of the foregoing.
9. The method of claim 1 , wherein the cancer is selected from bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, melanoma, mesothelioma, non-small cell lung carcinoma (NSCLC), ovarian cancer, renal cancer, bile duct cancer, multiple myeloma, adrenocortical carcinoma, head and neck cancer, and endometrial cancer.
10. The method of claim 1 , wherein the cancer is bladder cancer.
11. The method of claim 1 , wherein the cancer is colorectal cancer.
12. The method of claim 1 , wherein the cancer is esophageal cancer.
13. The method of claim 1 , wherein the cancer is gastric cancer.
14. The method of claim 1 , wherein the cancer is lung cancer.
15. The method of claim 1 , wherein the cancer is melanoma.
16. The method of claim 1 , wherein the cancer is mesothelioma.
17. The method of claim 1 , wherein the cancer is pancreatic cancer.
18. The method of claim 1 , wherein the cancer is non-small cell lung carcinoma (NSCLC).
19. The method of claim 1 , wherein the cancer is ovarian cancer.
20. The method of claim 1 , wherein the cancer is renal cancer.
21. The method of claim 1 , wherein the cancer is bile duct cancer.
22. The method of claim 1 , wherein the cancer is multiple myeloma.
23. The method of claim 1 , wherein the cancer is adrenocortical carcinoma.
24. The method of claim, 1 , wherein the cancer is head and neck cancer.
25. The method of claim 1 , wherein the cancer is endometrial cancer.
26. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a boronic acid ester derivative of the compound of the formula
or a pharmaceutically acceptable salt thereof, wherein the boronic acid moiety of the compound is esterified to form a boronic acid ester derivative.
27. The method of claim 26 , wherein the boronic acid ester derivative is capable of hydrolyzing under physiologic conditions to form the compound of the formula
28. The method of claim 26 , wherein the boronic acid ester derivative is a citrate or tartrate ester.
29. The method of claim 26 , wherein the cancer is selected from bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, melanoma, mesothelioma, non-small cell lung carcinoma (NSCLC), ovarian cancer, renal cancer, bile duct cancer, multiple myeloma, adrenocortical carcinoma, head and neck cancer, and endometrial cancer.
30. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a carboxylic acid ester derivative of the compound of the formula
or a pharmaceutically acceptable salt thereof, wherein the carboxylic acid ester on the pyrrolidine ring is esterified to form a carboxylic acid ester.
31. The method of claim 30 , wherein the carboxylic acid ester derivative is capable of hydrolyzing under physiologic conditions to form the compound of the formula
32. The method of claim 30 , wherein the cancer is selected from bladder cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, melanoma, mesothelioma, non-small cell lung carcinoma (NSCLC), ovarian cancer, renal cancer, bile duct cancer, multiple myeloma, adrenocortical carcinoma, head and neck cancer, and endometrial cancer.
33. The method of claim 1 , wherein the compound, or pharmaceutically acceptable salt thereof, is present as a solvate.
34. The method of claim 33 , wherein the solvate is a water solvate, methanol solvate, ethanol solvate or dimethylformamide solvate.
35. The method of claim 26 , wherein the compound, or pharmaceutically acceptable salt thereof, is present as a solvate.
36. The method of claim 35 , wherein the solvate is a water solvate, methanol solvate, ethanol solvate or dimethylformamide solvate.
37. The method of claim 30 , wherein the compound, or pharmaceutically acceptable salt thereof, is present as a solvate.
38. The method of claim 37 , wherein the solvate is a water solvate, methanol solvate, ethanol solvate or dimethylformamide solvate.